ATE267247T1 - Reagenz und verfahren zur inhibierung der n-ras expression - Google Patents

Reagenz und verfahren zur inhibierung der n-ras expression

Info

Publication number
ATE267247T1
ATE267247T1 AT97107706T AT97107706T ATE267247T1 AT E267247 T1 ATE267247 T1 AT E267247T1 AT 97107706 T AT97107706 T AT 97107706T AT 97107706 T AT97107706 T AT 97107706T AT E267247 T1 ATE267247 T1 AT E267247T1
Authority
AT
Austria
Prior art keywords
molecules
inhibiting
reagent
ras expression
pharmaceuticals
Prior art date
Application number
AT97107706T
Other languages
German (de)
English (en)
Inventor
Eugen Dr Uhlmann
Joachim Prof Dr Engels
Michaela Scherr
Arnold Prof Dr Ganser
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of ATE267247T1 publication Critical patent/ATE267247T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT97107706T 1996-05-24 1997-05-12 Reagenz und verfahren zur inhibierung der n-ras expression ATE267247T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96108326 1996-05-24

Publications (1)

Publication Number Publication Date
ATE267247T1 true ATE267247T1 (de) 2004-06-15

Family

ID=8222818

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97107706T ATE267247T1 (de) 1996-05-24 1997-05-12 Reagenz und verfahren zur inhibierung der n-ras expression

Country Status (9)

Country Link
US (1) US6037463A (ja)
EP (1) EP0808898B1 (ja)
JP (1) JPH1052264A (ja)
AT (1) ATE267247T1 (ja)
CA (1) CA2205075C (ja)
DE (1) DE69729145T2 (ja)
DK (1) DK0808898T3 (ja)
ES (1) ES2221942T3 (ja)
PT (1) PT808898E (ja)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005121370A2 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Oligomeric compounds that facilitate risc loading
US20040171030A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation
US20040147022A1 (en) * 1996-06-06 2004-07-29 Baker Brenda F. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US9096636B2 (en) * 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US7812149B2 (en) * 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
FR2812945B1 (fr) * 2000-08-10 2002-10-04 Aventis Pharma Sa Utilisation de la proteine grf1 et cellules exprimant la proteine grf1 pour le criblage de molecules
US20060009409A1 (en) * 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
WO2003064621A2 (en) * 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
WO2003064626A2 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Double-stranded oligonucleotides
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040248094A1 (en) * 2002-06-12 2004-12-09 Ford Lance P. Methods and compositions relating to labeled RNA molecules that reduce gene expression
US20040029275A1 (en) * 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
AU2003291755A1 (en) * 2002-11-05 2004-06-07 Isis Pharmaceuticals, Inc. Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use
WO2005044976A2 (en) * 2003-06-20 2005-05-19 Isis Pharmaceuticals, Inc. Oligomeric compounds for use in gene modulation
US8569474B2 (en) * 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en) * 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) * 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
KR20100065190A (ko) 2007-09-14 2010-06-15 닛토덴코 가부시키가이샤 약물 담체
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871838A (en) * 1985-07-23 1989-10-03 The Board Of Rijks Universiteit Leiden Probes and methods for detecting activated ras oncogenes
WO1991018913A1 (en) * 1990-06-07 1991-12-12 City Of Hope Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
AU7152191A (en) * 1990-06-07 1991-12-31 City Of Hope Ribozyme mediated reversal of transformation by cleavage of the hras oncogene rna
EP0552178B1 (en) * 1990-10-12 1997-01-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modified ribozymes
FI115214B (fi) * 1992-01-22 2005-03-31 Hoechst Ag Menetelmä oligonukleotidianalogien valmistamiseksi ja niiden käyttö
EP0641212A4 (en) * 1992-05-14 1997-05-21 Ribozyme Pharm Inc PROCESS AND REAGENT FOR PREVENTING THE DEVELOPMENT OF CANCER.
ATE151773T1 (de) * 1992-09-24 1997-05-15 Hoechst Ag Oligoribonucleotid- und ribozym-analoga mit terminalen 3'-3'-bzw.5'-5'-verknüpfungen
DE4408528A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung

Also Published As

Publication number Publication date
CA2205075A1 (en) 1997-11-24
JPH1052264A (ja) 1998-02-24
EP0808898A1 (en) 1997-11-26
ES2221942T3 (es) 2005-01-16
DK0808898T3 (da) 2004-09-27
US6037463A (en) 2000-03-14
EP0808898B1 (en) 2004-05-19
CA2205075C (en) 2011-08-09
DE69729145D1 (de) 2004-06-24
DE69729145T2 (de) 2005-06-09
PT808898E (pt) 2004-10-29

Similar Documents

Publication Publication Date Title
ATE267247T1 (de) Reagenz und verfahren zur inhibierung der n-ras expression
BR9908280A (pt) Inibidores de enzimas de fosfolipase
DE69528470D1 (de) Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel
PL332078A1 (en) Highly selective inhibitors of butyrylcholinesterase for trating and diagnosing the alzheimer disease and dementia
IL109780A0 (en) Saccharin derivative proteolytic enzyme inhibitors, their preparation and pharmaceutical compositions containing them
DE69812838T2 (de) Zusammensetzung und Verfahren zur Hemmung des Wachstums von Mikroorganismen auf der Grundlage von stabilisiertem Natriumhypobromit und Isothiazolonen
DE69435030D1 (de) Methode zur Detektion eines DNA Zielmoleküls
BR0312421A (pt) Uso de inibidores de cept e opcionalmente inibidores hmg coa redutase e/ou agentes anti-hipertensivos
DE69637579D1 (de) Methode zur Amplifizierung von Nukleinsäure und entsprechende Regenzien dafür
NO924309D0 (no) Sammensetninger og fremgangsmaater for modulering av rna-aktiviteter gjennom modifikasjon av 5' cap-strukturen til rna
DK1078054T3 (da) Monomer MP52/GDF-5 med knoglemorfogenetisk aktivitet og lægemiddel indeholdende samme til forebyggelse og behandling af brusk- og knoglesygdomme
WO1998032846A3 (en) Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos
DE50012013D1 (de) Verfahren und Vorrichtung zur Begrenzung des Drehmomentes zahnärztlicher und chirurgischer Handstücke
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
DE69805305D1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
EP0981535A4 (en) Methods for production and purification of nucleic acid molecules
DE69332375D1 (de) Hundecoronavirus s gen und verwendung davon
DE59509677D1 (de) Verfahren zur enzymatischen Spaltung von 2-Amino-4-methylphosphinobutansäureamid-Derivaten
ATE312179T1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
AU2002358580A1 (en) Methods of identifying genetic risk for and evaluating treatment of alzheimer's disease by determing single nucleotide polymorphisms
DK0808306T3 (da) Hidtil ukendte pyridin- eller pyridazinderivater, fremgangsmåder til fremstilling deraf og lægemidler indeholdende disse fo
DE69519388D1 (de) Verfahren zur herstellung von 2-(omega-alkoxycarbonylalkanoyl)-4-butanolid und langkettiger omega-hydroxycarbonsäure
DE59803623D1 (de) 11beta-arylsubstituierte 14,17-ethano estratriene, verfahren zur herstellung dieser verbindungen, sowie ihre verwendung zur herstellung von arzneimitteln
AUPP617498A0 (en) A method of modulating plant physiological processes and genetic sequences useful for same - ii

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0808898

Country of ref document: EP